Your session is about to expire
← Back to Search
Combination Chemotherapy + IM-862 for Ovarian Cancer
Study Summary
This trial is studying IM-862 to see how well it works in combination with standard chemotherapy in treating patients with ovarian or primary peritoneal cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Find a Location
Who is running the clinical trial?
Media Library
- I have not had gene therapy recently.I am not currently undergoing gene therapy.I am not currently receiving IL-2 treatment.I have not had chemotherapy for my current cancer.I am not currently taking GM-CSF.I am not currently taking any drugs that stop the formation of new blood vessels.I am not currently taking tamoxifen.I have not had radiation for my current cancer.I have stage III ovarian or primary peritoneal cancer.I had surgery to reduce my tumor size within the last 6 weeks.My surgery removed the cancer well, leaving no large remaining tumors.All my cancer outside the reproductive tract has been removed.My liver function tests are within normal ranges.My kidney function tests are within normal ranges.I haven't had any other cancer in the last 5 years.I don't have any serious illnesses that would shorten my life.I am in good overall health with no major medical or social issues affecting study participation.I am 18 years old or older.I can take care of myself but might not be able to do heavy physical work.I have not taken sargramostim recently.I have had surgery to remove my uterus, ovaries, and fallopian tubes.I have not received IL-2 treatment recently.I have not received hormone therapy for my current cancer.I am not receiving any other chemotherapy treatments.I haven't had biologic therapy for my current cancer.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the risks associated with this type of care?
"While there is data supporting the safety of this intervention, it is only from a Phase 2 trial, so Power rates its safety as a 2."
Are people still being recruited for this experiment?
"Unfortunately, this study is no longer recruiting patients. Although the last update was on November 5th 2013, it was originally posted on January 1st 2001. There are however 703 other clinical trials that are actively looking for participants."
In how many distinct places is this research being conducted?
"Right now, this trial has 19 sites where patients can be enrolled. If you are interested in enrolling, try to select a site that is close to your location to minimize travel time and costs. The locations include Saint Louis, Madison, Omaha and 16 other cities."
Share this study with friends
Copy Link
Messenger